2025-06-12-Jefferies-戴恩治疗公司（DYN）_管理层对话-罕见肌肉疾病加速审批路径的详尽FDA最新消息即将发布_11页_590kb

Summary of Equity Research Report on Dyne Therapeutics (DYN):

• Rating and Price Target: Equity research recommends a "Buy" rating with a price target of $50 (up from the current $14.57, representing a 243% upside). This is based on a high-probability scenario (50%+) of FDA clearance for the accelerated approval pathway, which could drive stock growth of 50-100%.

• FDA Update and Pathway Buy-in: The report anticipates a critical FDA regulatory update upcoming on the accelerated approval (AA) pathway for DYNE-101 (antisense oligonucleotide) in treating Myotonic Dystrophy Type 1 (DM1). There is confidence that the FDA will provide strong support for the AA approach, relying on 3-month splicing data as a surrogate endpoint. A Type C meeting in May 2025 discussed key data, including splicing efficacy correlation and statistical analysis plan (SAP) details, and the trend suggests FDA alignment.

• Clinical Progress: Key regulatory milestones include completing enrollment for the pivotal Phase II cohort in mid-2025 (up to N=48) in regions like Europe, New Zealand, and Australia. Pivotal data confirmation is expected by the first half of 2026, with US regulatory submissions for accelerated approval also targeted for H1:2026. The company is working on validating splicing markers and enrollment shows continuity with FDA reviewers.

• Market Context and Risks: The Street views the AA pathway as uncertain, citing competition from RNA-based therapies and regulatory challenges. However, Dyne Therapeutics is more optimistic than many analysts about its drug's differentiated efficacy and safety. Risks include unproven clinical outcomes, regulatory hurdles (e.g., FDA feedback changes), competitive pressure from rivals like RNA therapeutics and other gene dystrophy programs, and uncertainties in confirmatory studies.

• Stock Potential: If the FDA confirms the AA pathway, DYN stock could surge due to reduced risk and positive market reception. Opposite scenarios (if AA is not cleared) involve longer timelines but high success potential if pivotal data is favorable. A probability-adjusted valuation assigns a significant upside based on near-term events.

• Company Overview: Dyne Therapeutics develops treatments for rare muscle diseases using its proprietary FORCE platform, with DYNE-101 advancing in DM1 and DYNE-251 (antisense oligo) for Duchenne Muscular Dystrophy (DMD Exon 51) expected to enter pivotal stages soon. The company's lead programs are at critical phases, with ongoing partnerships and market dynamics shaping valuation.